September 18th 2023
An exclusive Urology Times survey measured US-based urologists’ uptake, access to, and indications for utilizing prostate-specific membrane antigen-targeting agents.
September 15th 2023
September 14th 2023
Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
Register Now!
Addressing Healthcare Inequities: Overcoming Challenges in the Equitable Management of Idiopathic Pulmonary Fibrosis
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Medical Crossfire®: Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More